Loading…
Loading…
CSBTF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CSBTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CSBTF and 80,000+ other tickers.
See exactly how CSBTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CSBTF and 80,000+ other tickers.
Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in…
Kuros Biosciences AG (CSBTF) Q2 2026 Earnings Call Transcript
Kuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million) Direct MagnetOs™ product sales increased by 51% to USD 42.9 million (Q1 2025: USD 28.4 million) Group EBITDA reached USD 2.9 million (Q1 2025: EBITDA of USD 2.0 million) Group adjusted EBITDA* amounted to USD 5.7 million, equaling a margin of 13.1% (Q1 2025: USD 3.3 million at 11.6%) Cash and cash equivalents totaled USD 15.7 million, compared to USD 19.8 million as of December 31, 2025, reflecting investments in the diversification and optimization of production capacity to support long-term growth Clinical & Operational Highlights Kuros continued to achieve significant progress in its extremities segment along with strong adoption of MagnetOs MIS in minimally invasive surgeries, reflecting broader adoption across various specialties in multiple care settings A retrospective study led by Dr. Mark Eskander was published in Spine Open and reported an overall fusion rate of 87% for MagnetOs Easypack Putty in a high-risk patient population assessing 70 posterior lumbar fusion patients, with an 84.2% fusion rate in patients assessed at